Publications of Aaron Cumpston, PharmD.

Superior serum concentrations with posaconazole delayed-release tablets compared to suspension formulation in hematological malignancies.
Cumpston AD, Caddell R, Shillingburg A, Lu X, Wen S, Hamadani M, Craig M, Kanate AS.
Antimicrob Agents Chemother. 2015;59(8):4424-4428.

PMC4505228.

Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use.
Veltri L, Cumpston AD, Shillingburg AS, Wen S, Luo J, Leadmon S, Watkins K, Craig M, Hamadani M, Kanate AS.
Cytotherapy. 2015;17(12):1785-1792.

PMC4700501.

Diacetyl increases sensory innervation and substance p production in rat trachea.
Goravanahally MP, Hubbs AF, Fedan JS, Kashon ML, Battelli LA, Mercer RR, Goldsmith WT, Jackson MC, Cumpston AD, Frazer DG, Dey RD.
Toxicol Pathol. 2014;42(3):582-590.


Predictors and impact of thirty-day readmission on patient outcomes and health care costs after reduced-toxicity conditioning allogeneic hematopoietic cell transplantation.
Rauenzahn S, Truong Q, Cumpston AD, Goff L, Leadmon S, Evans K, Zhang J, Wen S, Craig M, Hamadani M, Kanate AS.
Biol Blood Marrow Transplant. 2014;20(3):415-420.

PMC4557764.

Impact of the duration of antiviral prophylaxis on rates of varicella-zoster virus reactivation disease in autologous hematopoietic cell transplantation recipients.
Truong Q, Veltri L, Kanate AS, Hu Y, Craig M, Hamadani M, Cumpston AD.
Ann Hematol. 2014;93(4):677-682.


Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies.
Awan FT, Kochuparambil ST, Falconer DE, Cumpston AD, Leadmon S, Watkins K, DeRemer D, Jillella A, Craig M, Hamadani M.
Bone Marrow Transplant. 2013;48(10):1279-1284.


Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.
Chaudhary LN, Awan FT, Cumpston AD, Leadmon S, Watkins K, Tse WW, Craig M, Hamadani M.
J Clin Apher. 2013;28(5):359-367.


Extended follow-up of an antibiotic cycling program for the management of febrile neutropenia in a hematologic malignancy and hematopoietic cell transplantation unit.
Cumpston AD, Craig M, Hamadani M, Abraham J, Hobbs GR, Sarwari AR.
Transpl Infect Dis. 2013;15(2):142-149.


Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host disease.
Hamadani M, Gibson LF, Remick SC, Wen S, Petros WP, Tse WW, Brundage KM, Vos JA, Cumpston AD, Bunner P, Craig M.
J Clin Oncol. 2013;31(35):4416-4423.

PMC3842909.

Salvage bone marrow harvest in patients failing Plerixafor-based stem cell mobilization attempt: feasibility and autologous transplantation outcomes.
Kanate AS, Watkins K, Cumpston AD, Craig M, Hamadani M.
Biol Blood Marrow Transplant. 2013;19(7):1133-1135.


Molecular insights into the progression of crystalline silica-induced pulmonary toxicity in rats.
Sellamuthu R, Umbright C, Roberts JR, Cumpston AD, McKinney W, Chen BT, Frazer D, Li S, Kashon ML, Joseph PN.
J Appl Toxicol. 2013;33(4):301-312.


Incidence and pattern of graft-versus-host disease in patients undergoing allogeneic transplantation after nonmyeloablative conditioning with total lymphoid irradiation and antithymocyte globulin.
Veltri L, Regier M, Cumpston AD, Leadmon S, Tse WW, Craig M, Hamadani M.
Bone Marrow Res. 2013;2013:414959

PMC3652129.

Plerixafor salvage is safe and effective in hard-to-mobilize patients undergoing cemotherapy and filgrastim-based peripheral blood progenitor cell mobilization.
Awan FT, Kochuparambil ST, DeRemer D, Cumpston AD, Craig M, Jillella A, Hamadani M.
J Oncol. 2012;2012:931071

PMC3335320.

Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell obilization in patients with multiple myeloma treated with novel induction therapies.
Hamadani M, Kochuparambil ST, Osman S, Cumpston AD, Leadmon S, Bunner P, Watkins K, Morrison D, Speir E, DeRemer D, Kota V, Jillella A, Craig M, Awan FT.
Biol Blood Marrow Transplant. 2012;18(7):1128-1135.


Evaluation of an alternative posaconazole prophylaxis regimen in haematological malignancy patients receiving concomitant stress ulcer prophylaxis.
Ross AL, Slain D, Cumpston AD, Bryant AM, Hamadani M, Craig M.
Int J Antimicrob Agents. 2012;40(6):557-561.


Impact of alcohol-impregnated port protectors and needleless neutral pressure connectors on central line-associated bloodstream infections and contamination of blood cultures in an inpatient oncology unit.
Sweet MA, Cumpston AD, Briggs F, Craig M, Hamadani M.
Am J Infect Control. 2012;40(10):931-934.


Azacitidine-associated Sweet's syndrome.
Trickett HB, Cumpston AD, Craig M.
Am J Health Syst Pharm. 2012;69(10):869-871.


A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis.
Bryant AM, Slain D, Cumpston AD, Craig M.
Int J Antimicrob Agents. 2011;37(3):266-269.


Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning.
Hamadani M, Craig M, Phillips GS, Abraham J, Tse WW, Cumpston AD, Gibson LF, Remick SC, Bunner P, Leadmon S, Elder P, Hofmeister C, Penza S, Efebera Y, Andritsos L, Garzon R, Benson DM, Blum W, Devine SM.
Hematol Oncol. 2011;29(4):202-210.

PMC3557914.

Higher infused CD34+ cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral blood hematopoietic cell transplantation.
Kanate AS, Craig M, Cumpston AD, Saad A, Hobbs GR, Leadmon S, Bunner P, Watkins K, Bulian D, Gibson LF, Abraham J, Remick SC, Hamadani M.
Hematol Oncol Stem Cell Ther. 2011;4(4):149-156.


Onset and complications of varicella zoster reactivation in the autologous hematopoietic cell transplant population.
Rogers JE, Cumpston AD, Newton MD, Craig M.
Transpl Infect Dis. 2011;13(5):480-484.


Bendamustine-associated hemolytic anemia.
Glance LE, Cumpston AD, Kanate AS, Remick SC.
Ann Pharmacother. 2009;43(11):1903-1906.


The clinical impact of antibacterial prophylaxis and cycling antibiotics for febrile neutropenia in a hematological malignancy and transplantation unit.
Craig M, Cumpston AD, Hobbs GR, Devetten MP, Sarwari AR, Ericson SG.
Bone Marrow Transplant. 2007;39(8):477-482.



Cumpston AD, Bulian D, Kanate AS, Weisenborn R, Bunner P, Craig M, Ericson SG.
Biol Blood Marrow Transplant. 2007;13:37



Cumpston AD.
Community Oncol. 2007;4:386


Use of rituximab in refractory autoimmune thrombocytopenia following an autologous stem cell transplant.
Price S, Cumpston AD, Altaha R.
Hematology. 2006;11(1):43-44.



Craig M, Cumpston AD, Shields R, Devetten MP, Sarwari AR, Ericson SG.
Biol Blood Marrow Transplant. 2005;11:89-90.